Positive attributes of anti-TERT CD4 T-Helper Type 1 immune responses in melanoma
Affiliation
Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, SpainIssue Date
2021
Metadata
Show full item recordAbstract
Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.Citation
Nagore E, Virós A, Kumar R. Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma [Internet]. Journal of Investigative Dermatology. Elsevier BV; 2021.Journal
Journal of Investigative DermatologyDOI
10.1016/j.jid.2021.09.005PubMed ID
34666894Additional Links
https://dx.doi.org/10.1016/j.jid.2021.09.005Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jid.2021.09.005
Scopus Count
Collections
Related articles
- Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
- Authors: Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O
- Issue date: 2022 Feb
- Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.
- Authors: Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O
- Issue date: 2019 Aug
- Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
- Authors: Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ
- Issue date: 2002 Sep 2
- Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
- Authors: Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O
- Issue date: 2012 Nov 15
- Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.
- Authors: Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O
- Issue date: 2016 May